eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2024
vol. 41
 
Share:
Send email
Share:
abstract:
Original paper

Vaccination against the SARS-CoV-2 virus in patients undergoing Hymenoptera venom immunotherapy

Wojciech Żurek
1
,
Magdalena Baron
1
,
Łukasz Moos
1
,
Katarzyna Kapeluszna
1
,
Liwia Starczewska-Dymek
1
,
Zenon Brzoza
1

  1. Department of Internal Diseases, Allergology, Endocrinology and Gastroenterology, Institute of Medical Sciences, University of Opole, Opole, Poland
Adv Dermatol Allergol 2024; XLI (2): 215-219
DOI: https://doi.org/10.5114/ada.2024.139136
Online publish date: 2024/04/24
View full text Get citation
 
Introduction:
The SARS-CoV-2 epidemic has unquestionably left a significant mark on the global healthcare system. Implementation of the commonly available vaccinations against COVID-19 is intended to reduce the risk of a severe course of the disease. Due to a very brief development period of the new vaccines, concerns have appeared among the public with regard to the possible adverse effects of the newly-developed preparations, as well as to the risks of causing allergic reactions. Regular medical observation during the Hymenoptera venom immunotherapy provides significant possibilities to note any potential adverse effects of vaccines against COVID-19, as well as of complications of an experienced SARS CoV-2 infection.

Aim:
To assess the issues connected with vaccination against COVID-19, complications following vaccination, as well as incidence and course of the disease among patients undergoing venom immunotherapy (VIT) due to an allergy to Hymenoptera venom.

Material and methods:
We investigated 37 persons aged 19 to 70 (20 women; 17 men) undergoing Hymenoptera venom immunotherapy in our department.

Results:
21.6% have experienced an infection with the SARS-CoV-2 virus, confirmed by a diagnostic test. No person participating in the study had experienced a severe infection which would require hospitalization. Elderly people have been vaccinated statistically significantly more often than young people.

Conclusions:
The risk related to vaccination in this group of patients does not seem to be higher than in the general population.

keywords:

COVID-19, Hymenoptera immunotherapy, vaccination
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.